When are we going to take modifiable risk factors more seriously in multiple sclerosis?
- Published in:
- 2017
- By:
- Publication type:
- Editorial
Works matching IS 13524585 AND DT 2017 AND VI 23 AND IP 4
Results: 20
1
2
Indirect comparisons of treatment effects: Network meta-analyses.
- Published in:
- Multiple Sclerosis Journal, 2017, v. 23, n. 4, p. 510, doi. 10.1177/1352458517690272
- By:
- Publication type:
- Article
3
A systematic review of the effects of modifiable risk factor interventions on the progression of multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2017, v. 23, n. 4, p. 513, doi. 10.1177/1352458517690271
- By:
- Publication type:
- Article
4
Imaging of microglial activation in MS using PET: Research use and potential future clinical application.
- Published in:
- Multiple Sclerosis Journal, 2017, v. 23, n. 4, p. 496, doi. 10.1177/1352458516674568
- By:
- Publication type:
- Article
5
Measuring treatment satisfaction in MS: Is the Treatment Satisfaction Questionnaire for Medication fit for purpose?
- Published in:
- Multiple Sclerosis Journal, 2017, v. 23, n. 4, p. 604, doi. 10.1177/1352458516657441
- By:
- Publication type:
- Article
6
A systematic review of modifiable risk factors in the progression of multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2017, v. 23, n. 4, p. 525, doi. 10.1177/1352458517690270
- By:
- Publication type:
- Article
7
Inadequate outcome measures are the biggest impediment to successful clinical trials in progressive MS -- Commentary.
- Published in:
- Multiple Sclerosis Journal, 2017, v. 23, n. 4, p. 508, doi. 10.1177/1352458516674368
- By:
- Publication type:
- Article
8
Comment on extensive white matter lesions after 2 years of fingolimod: Progressive multifocal leukoencephalopathy or MS relapse?
- Published in:
- Multiple Sclerosis Journal, 2017, v. 23, n. 4, p. 617, doi. 10.1177/1352458516682859
- By:
- Publication type:
- Article
9
Extensive white matter lesions after 2 years of fingolimod: Progressive multifocal leukoencephalopathy or MS relapse?
- Published in:
- 2017
- By:
- Publication type:
- Case Study
10
Biotin supplementation in MS clinically valuable but can alter multiple blood test results.
- Published in:
- 2017
- By:
- Publication type:
- Letter to the Editor
11
Reply to Letter to the Editor: Biotin supplementation in MS clinically valuable but can alter multiple blood test results by Siddiqui U, et al.
- Published in:
- 2017
- By:
- Publication type:
- Letter to the Editor
12
Inadequate outcome measures are the biggest impediment to successful clinical trials in progressive MS -- NO.
- Published in:
- Multiple Sclerosis Journal, 2017, v. 23, n. 4, p. 506, doi. 10.1177/1352458516671205
- By:
- Publication type:
- Article
13
Role of IL-17-producing lymphocytes in severity of multiple sclerosis upon natalizumab treatment.
- Published in:
- Multiple Sclerosis Journal, 2017, v. 23, n. 4, p. 567, doi. 10.1177/1352458516658559
- By:
- Publication type:
- Article
14
Inadequate outcome measures are the biggest impediment to successful clinical trials in progressive MS -- YES.
- Published in:
- Multiple Sclerosis Journal, 2017, v. 23, n. 4, p. 505, doi. 10.1177/1352458516671821
- By:
- Publication type:
- Article
15
Trajectory of MS disease course for men and women over three eras.
- Published in:
- Multiple Sclerosis Journal, 2017, v. 23, n. 4, p. 534, doi. 10.1177/1352458516655478
- By:
- Publication type:
- Article
16
Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study.
- Published in:
- Multiple Sclerosis Journal, 2017, v. 23, n. 4, p. 588, doi. 10.1177/1352458516657440
- By:
- Publication type:
- Article
17
Neurostatus e-Scoring improves consistency of Expanded Disability Status Scale assessments: A proof of concept study.
- Published in:
- Multiple Sclerosis Journal, 2017, v. 23, n. 4, p. 597, doi. 10.1177/1352458516657439
- By:
- Publication type:
- Article
18
Dentate nucleus connectivity in adult patients with multiple sclerosis: functional changes at rest and correlation with clinical features.
- Published in:
- Multiple Sclerosis Journal, 2017, v. 23, n. 4, p. 546, doi. 10.1177/1352458516657438
- By:
- Publication type:
- Article
19
Working memory network dysfunction in relapse-onset multiple sclerosis phenotypes: A clinical-imaging evaluation.
- Published in:
- Multiple Sclerosis Journal, 2017, v. 23, n. 4, p. 577, doi. 10.1177/1352458516656809
- By:
- Publication type:
- Article
20
Grey matter atrophy is associated with disability increase in natalizumab-treated patients.
- Published in:
- Multiple Sclerosis Journal, 2017, v. 23, n. 4, p. 556, doi. 10.1177/1352458516656808
- By:
- Publication type:
- Article